BOHEMIA, N.Y.--(BUSINESS WIRE)--Advanced BioPhotonics Inc. (OTCBB: ABPH) announced today that it has completed its initial phase and review of the clinical trial protocol previously announced earlier this year. This trial is investigating the use of Advanced BioPhotonics’ patented BioScanIR® System, together with its proprietary DIRI® method of dynamic infrared imaging in detecting and assessing pigmented lesions of the skin including melanoma and other forms of skin cancer.
